The Medicines Patent Pool (MPP) is a Unitaid-backed international organisation founded in July 2010, based in Geneva, Switzerland. Its public health driven business model aims to lower the prices of HIV, tuberculosis and hepatitis C medicines and facilitate the development of better-adapted HIV treatments through voluntary licensing and patent pooling. Its goal is to improve access to affordable and appropriate HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries (LMIC). Economics research finds evidence that the pool increases generic diffusion in LMIC and upstream innovation. In May 2020, the MPP become an implementing partner of the WHO's Covid-19 Technology Access Pool (C-TAP).